Early effects of sodium valproate monotherapy on serum paraoxonase/arylesterase activities

References

• Garcia‐Morales I., Rieger J. S., Gil‐Nagel A., Fernadez J. L. H. Antiepileptic drugs: scientific evidence to clinical practice. Neurologist 2007; 13 Suppl 1: S20–8
   Google Scholar
• Calabrese J. R., Delucchi G. A. Spectrum of efficacy of valproate in 55 patients with rapid‐cycling bipolar disorders. Am J Psychiatry 1990; 147: 431–4
   PubMed Web of Science ®Google Scholar
• Shelton C. E., Connelly J. F. Valproic acid a migraine prophylaxis alternative. Ann Pharmacother 1996; 30: 865–6
   PubMed Web of Science ®Google Scholar
• Levy R. H. Antiepileptic drugs, 5th edn. Lippincott Williams and Wilkins, Philadelphia 2002; 843–5
   Google Scholar
• Gilfum‐Sherki Y., Rosenbaum Z., Mclamed E., Oflen D. Antioxidant therapy in acute central nervous system injury. Curr State Pharmacol Rev 2000; 54: 271–84
   Google Scholar
• Finker T., Holbrook N. J. Oxidants, oxidative stress and the biology of aging. Nature (Lond) 2000; 408: 239–47
   PubMedGoogle Scholar
• Sonmez F. M., Demir E., Orem A., Yildirmis S., Orhan F., Aslan A., et al. Effect of antiepileptic drugs on plasma lipids, lipoprotein(a) and liver enzymes. J. Child Neurol 2006; 21: 70–4
   PubMed Web of Science ®Google Scholar
• Tekgul H., Demir N., Gokben S. Serum lipid profile in children receiving anti‐epileptic drug monotherapy: Is it atherogenic?. J Pediatr Endocrinol Metab 2006; 19: 1151–5
   PubMedGoogle Scholar
• Voudris K. A., Attilakos A., Katsarou E., Drakatos A., Dimou S., Mastroyiannis S., et al. Early and persistent increase in serum lipoprotein(a) concentration in epileptic children treated with carbamazepine and sodium valproate monotherapy. Epilepsy Res 2006; 70: 211–17
   PubMed Web of Science ®Google Scholar
• Schulpis K. H., Lazaropoulou C., Regoutas S., Karikas G. A., Margeli A., Tsakiris S., et al. Valproic acid monotherapy induces DNA oxidative damage. Toxicology 2006; 217: 228–32
   PubMed Web of Science ®Google Scholar
• La Du B. N. Structural and functional diversity of paraoxonases. Natural Medicine 2 1996; 1186–7
   Google Scholar
• Josse D., Lockridge O., Xie W., Bartels C. F., Schopfer L. M., Masson P. The active site of human paraoxonase (PON1). J Appl Toxicol 2001; 21 Suppl: 57–511
   Google Scholar
• Nguyen D. S., Sok D. E. Oxidative inactivation of paraoxonase 1, an antioxidant protein and its effect on antioxidant action. Free Rad Res 2003; 37: 1319–30
   PubMed Web of Science ®Google Scholar
• Aviram M., Billecke S., Sorenson R., Bisgaier C., Newton R., Rosenblat M., et al. Paraoxonase active site required for protective against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities; selective action of human paraoxonase alloenzymes Q and R. Arterioscler Thromb Vasc Biol 1998; 18: 1617–24
   PubMed Web of Science ®Google Scholar
• Marathe G. K., Zimmerman G. A., McIntyre T. M. Platelet‐activating factor acetylhydrolase, and not paraoxonase1, is the oxidized phospholipids hydrolase of high density lipoprotein particles. J Biol Chem 2003; 278: 3937–47
   PubMed Web of Science ®Google Scholar
• Schulpis K. H., Tsironi M., Skenderi K., Lazaropoulou C., Parthimos N., Reclos G., et al. Dramatic reduction of erythrocyte glucose‐6‐phosphate dehydrogenase activity in athletes participating in the ultradistance foot race “Spartathlon”. Scand J Clin Lab Invest 2007; 12: 1–7
   Google Scholar
• Charlton‐Menys V., Liu Y., Durrington P. N. Semiautomated method for determinations of serum paraoxonase activity using paraoxon as substrate. Clin Chem 2006; 52: 453–7
   PubMedGoogle Scholar
• Schulpis K. H., Bartzeliotou A., Tsakiris S., Gounaris A., Papassotiriou I. Serum paraoxonase/arylesterase activities in phenylketonuric patients on diet. Eur J Clin Nutr 2007; 61: 803–8
   PubMedGoogle Scholar
• Bryan A. E., Dreifuss F. E. Valproic acid hepatic fatalities USA experience since. Neurology 1996; 46: 465–9
   PubMedGoogle Scholar
• Jeavons P. M. Non‐dose‐related side effects of valproate. Epilepsia 1984; 25: 55–6
   Google Scholar
• Tong V., Chang T. K., Chen J., Abbott F. S. The effect of valproic acid on hepatic and plasma levels of 15‐F2t‐isoprostane in rats. Free Radic Biol Med 2003; 34: 1435–46
   PubMed Web of Science ®Google Scholar
• Halliwell B., Gutlerdge J. M. C. Free radicals in biology and medicine, 2nd edn. Clarendon Press, Oxford 1989; 110–19
   Google Scholar
• Simon H. U., Yehia A., Levi‐Schaffer F. Role of reactive oxygen species (ROS) in apoptotic induction. Apoptosis 2000; 5: 415–18
   PubMed Web of Science ®Google Scholar
• Karikas G. A., Shulpis K. H., Barzeliotou A., Karakonstantakis T., Georgala S., Kanavaki I., et al. Lipids, lipoproteins, apoliproteins, selected trace elements and minerals in children on valproic acid monotherapy. Basic Clin Pharmacol Toxicol 2006; 98: 599–603
   PubMed Web of Science ®Google Scholar
• Ferre N., Camps J., Cabre M., Paul A., Joven J. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism 2001; 9: 997–1000
   Google Scholar
• Ferre N., Camps J., Prats E., Villela E., Paul A., Figuera L., et al. Serum paraoxonase1 activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002; 48: 262–8
   Google Scholar
• Heinecke J. W., Lusis A. J. Paraoxonase‐gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis?. Am J Hum Genet 1998; 62: 20–4
   PubMed Web of Science ®Google Scholar
• Gur M., Yildiz A., Demirbag R., Yilmaz R., Aslan M., Ozdogru I., et al. Paraoxonase and arylesterase activities in patients with cardiac syndrome X, and their relationship with oxidative stress markers. Coronary Artery Dis 2007; 18: 89–95
   PubMed Web of Science ®Google Scholar
• Schulpis K. H., Karikas G. A., Tjamourakis J., Tsakiris S. Low serum biotinidase activity in children with valproic acid monotherapy. Epilepsia 2001; 56: 912–14
   Google Scholar